Sponsor:
BicycleTx Limited
Code:
NCT04561362
Conditions
Urinary Bladder Neoplasm
Triple Negative Breast Neoplasms
Hormone Receptor Positive, HER2-negative Neoplasms
Hormone Receptor Positive, HER2-low Neoplasms
Breast Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BT8009
Pembrolizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by BicycleTx Limited on 2024-09-27.